PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 178 filers reported holding PUMA BIOTECHNOLOGY INC in Q1 2018. The put-call ratio across all filers is 0.98 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $74,556,000 | -17.4% | 1,095,612 | +19.9% | 2.88% | -26.7% |
| Q4 2017 | $90,307,000 | -16.8% | 913,573 | +0.8% | 3.93% | -26.7% |
| Q3 2017 | $108,570,000 | +44.4% | 906,642 | +5.4% | 5.36% | +17.0% |
| Q2 2017 | $75,204,000 | +17.2% | 860,456 | -50.1% | 4.58% | +9.9% |
| Q1 2017 | $64,185,000 | +62.1% | 1,725,414 | +33.7% | 4.17% | +22.0% |
| Q4 2016 | $39,607,000 | -10.8% | 1,290,140 | +94.8% | 3.41% | -3.3% |
| Q3 2016 | $44,406,000 | +149.9% | 662,286 | +605.6% | 3.53% | +82.6% |
| Q4 2014 | $17,766,000 | +45.9% | 93,865 | +84.0% | 1.93% | +37.6% |
| Q3 2014 | $12,173,000 | -32.1% | 51,025 | -70.4% | 1.41% | -34.3% |
| Q1 2014 | $17,922,000 | -25.0% | 172,092 | -25.4% | 2.14% | -27.4% |
| Q4 2013 | $23,882,000 | +30.8% | 230,673 | -32.2% | 2.95% | +7.2% |
| Q3 2013 | $18,253,000 | -23.8% | 340,165 | -37.0% | 2.75% | -34.9% |
| Q2 2013 | $23,960,000 | +34.0% | 539,994 | +0.9% | 4.22% | +28.6% |
| Q1 2013 | $17,878,000 | – | 535,428 | – | 3.28% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HARVARD MANAGEMENT CO INC | 600,000 | $45,216,000 | 3.56% |
| Avalon Global Asset Management LLC | 32,900 | $2,479,000 | 1.79% |
| CORNERSTONE CAPITAL MANAGEMENT LLC | 495,145 | $37,314,000 | 1.58% |
| BB BIOTECH AG | 521,991 | $39,337,000 | 1.25% |
| WEATHERBIE CAPITAL, LLC | 137,041 | $10,327,000 | 1.20% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,686,668 | $428,527,000 | 1.19% |
| TOBAM | 318,384 | $23,994,000 | 0.94% |
| Orbimed Advisors | 1,195,500 | $90,093,000 | 0.91% |
| Capital International Sarl | 109,405 | $8,245,000 | 0.74% |
| CAPITAL INTERNATIONAL LTD /CA/ | 145,697 | $10,980,000 | 0.73% |